adenosine amine congener has been researched along with 3-nitropropionic acid in 1 studies
| Studies (adenosine amine congener) | Trials (adenosine amine congener) | Recent Studies (post-2010) (adenosine amine congener) | Studies (3-nitropropionic acid) | Trials (3-nitropropionic acid) | Recent Studies (post-2010) (3-nitropropionic acid) |
|---|---|---|---|---|---|
| 29 | 0 | 5 | 970 | 1 | 327 |
| Protein | Taxonomy | adenosine amine congener (IC50) | 3-nitropropionic acid (IC50) |
|---|---|---|---|
| Isocitrate lyase | Candida albicans | 7.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bantubungi, K; Blum, D; d'Alcantara, P; Galas, MC; Gall, D; Schiffmann, SN | 1 |
1 other study(ies) available for adenosine amine congener and 3-nitropropionic acid
| Article | Year |
|---|---|
The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity.
Topics: Adenosine; Animals; Behavior, Animal; Binding, Competitive; Body Weight; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Dystonia; Enkephalins; Hindlimb; Huntington Disease; In Vitro Techniques; Male; Mitochondria; Motor Activity; Neuroprotective Agents; Neurotoxins; Nitro Compounds; Propionates; Purinergic P1 Receptor Agonists; Rats; Rats, Inbred Lew; Reproducibility of Results; RNA, Messenger; Succinate Dehydrogenase; Synaptic Transmission; Treatment Outcome | 2002 |